HS-10390 for IgA Nephropathy: Safety and Effectiveness Study
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug, HS-10390, to see if it can help people with IgA nephropathy. You may qualify if you have the condition, are on stable blood pressure medication, and meet certain kidney function and lab criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with primary IgA nephropathy (confirmed by kidney biopsy).
- You have been on a stable dose of blood pressure medication (ACEI or ARB) for at least 12 weeks.
- Your urine protein level is at least 0.75 grams per 24 hours.
- Your kidney function (estimated GFR) is 30 or higher.
- Your blood pressure is controlled (systolic between 100-150, diastolic between 60-100).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether choosing treatment based on your personal kidney findings can improve outcomes in adults with IgA nephropathy (IgAN). It may help by matching therapy to the type and severity of kidney damage seen on biopsy.
This trial tests a new treatment called HS-10542 for people with IgA nephropathy, a kidney disease. It aims to see if the drug can safely reduce protein in the urine and help protect kidney function.
This phase 3 trial tests an experimental drug (HRS-5965) for people with IgA nephropathy (a kidney disease). It aims to find out if the drug can help reduce protein in the urine and protect kidney function. To join, you must have had a kidney biopsy showing IgA nephropathy within the past 8 years and have significant protein in your urine despite taking standard treatments.
This study continues treatment with an experimental medicine called HSK39297 for people with IgA nephropathy, a condition where the immune system damages the kidneys. The trial will track how safe and effective the medicine is over time in people who already completed an earlier study.
This phase 2a trial tests an experimental drug called RG002C0106 in people with primary IgA nephropathy. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
This trial tests a medicine called CM313 in people with IgA nephropathy, a kidney disease. It may help reduce protein in the urine, which is a sign of kidney damage.
Hear when a new Immunoglobulin A Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.